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Abstract: Serum zinc concentration (SZC) is used widely to assess population-level zinc status.
Its concentration decreases during inflammatory responses, which can affect the interpretation of
the results. This study aimed to re-estimate the prevalence of zinc deficiency in Malawi based on
the 2015–2016 Malawi Micronutrient Survey (MNS) data, by adjusting SZC measures with markers
of inflammation. SZC and inflammation data from 2760 participants were analysed. Adjustments
were made using: (1) The Internal Correction Factor (ICF) method which used geometric means, and
(2) The Biomarkers Reflecting Inflammation and Nutritional Determinants of Anemia (BRINDA)
method, which used linear regression. Mean SZC values increased significantly when adjustments
were made by either ICF or BRINDA (p < 0.001). The national prevalence of zinc deficiency decreased
from 62% to 59%, after ICF adjustment, and to 52% after BRINDA adjustment. ICF and BRINDA
values of SZC were highly correlated (p < 0.001, r = 0.99), but a Bland–Altman plot showed a lack
of agreement between the two methods (bias of 2.07 µg/dL). There was no association between the
adjusted SZC and stunting, which is a proxy indicator for zinc deficiency. Inflammation adjustment
of SZC, using ICF or BRINDA, produces lower estimates of zinc deficiency prevalence, but the lack
of agreement between the adjustment methods warrants further research. Furthermore, the lack of
association between SZC and stunting highlights the need to explore other biomarkers and proxies of
population zinc assessment. This study demonstrates the importance of considering inflammatory
confounders when reporting SZC, to ensure accuracy and to support policy decision making.
Keywords: zinc; biomarkers; inflammation; C-reactive protein (CRP); alpha 1-acid glycoprotein
(AGP); children; women of reproductive age
1. Introduction
Zinc is an important micronutrient in the human body and it plays various biochemical roles
characterized by catalytic, structural and regulatory functions [1]. Zinc deficiency can cause ailments
in all age groups such as poor growth, compromised immune system, cognitive impairment, delayed
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sexual maturation and poor pregnancy outcomes [2]. Zinc deficiency is a global challenge, and more
than 20% of children and women are estimated to be zinc deficient [3]. Although many countries
lack national-level data on population zinc status, some countries such as Malawi conduct a periodic
National Micronutrient Survey (MNS) in which biomarkers of zinc status are analysed.
Three main indicators (plasma/serum zinc concentration, dietary data and stunting) are
recommended for use in the assessment of population-level zinc status [1]. Serum zinc is a biochemical
indicator and it reflects individual zinc status to estimate zinc deficiency, compared to the other two
indicators, which only predict the risk [2,4,5]. Despite this recommendation, serum zinc concentration
(SZC) has limitations as a biomarker for zinc assessment, because it is affected by many factors such as
inflammation, circadian variation and fasting status [2,6,7]. It is, nevertheless, the most commonly used
indicator for population zinc status assessment; it was recently used in the Malawi MNS to assess zinc
status of a nationally representative sample of men, women of reproductive age (WRA), school-age
children (SAC), and pre-school children (PSC) [8]. Results from this survey indicated a zinc deficiency
prevalence ranging from 60%–66% across these demographic groups. This prevalence is the highest
recorded national prevalence in sub-Saharan Africa, and one of the highest globally [3]. However,
the results were reported without adjusting for inflammation, which is an important confounder.
Inflammation induces a series of biochemical responses, which causes changes in serum and
plasma concentration of acute phase reactants (APRs) in the body [9]. These APRs include nutrients
such as zinc, which decrease in concentration, and ferritin, which increase in concentration. The SZC
of an inflamed individual will thus be depressed below the actual value causing an artificial increase
of the deficiency prevalence estimate. Several methods can be used to control for the effects of
inflammation when reporting results of APR nutrients. The two most widely recommended methods
use mathematical calculations to adjust the micronutrient concentrations [10–18]. These methods are
reliant on an individuals’ inflammation status, with inflammatory markers being measured at the
same time as the micronutrient. The commonly measured biomarkers of inflammation in surveys
are C-reactive protein (CRP) and alpha 1-acid glycoprotein (AGP), both of which are used to make
the adjustments. The first recommended method is the Internal Correction Factor (ICF), which was
suggested by Thurnham et al. [11] For this approach, geometric means are calculated and used to
develop correction factors to adjust the micronutrient values. The other recommended method uses
linear regression to adjust the values on a continuous scale. It was developed by the Biomarkers
Reflecting Inflammation and Nutritional Determinants of Anemia (BRINDA) project, and is referred
to as the BRINDA method [19]. Studies have shown that both methods can adjust concentrations of
different micronutrients [11,13,18,20–25] and more specifically, concentrations of zinc in PSC [14,15],
adults [16], and the elderly [12]. Currently, no studies have applied these methods, to adjust for zinc
deficiency in a nationally representative sample of all age and gender groups.
The aim of this study was to re-estimate the prevalence of zinc deficiency in Malawi, based
on the 2015–2016 Malawi MNS data, by adjusting SZC measures with markers of inflammation.
The specific primary objectives were to: (a) re-estimate the prevalence of zinc deficiency in the MNS
sample population by adjusting SZC values for inflammation, using ICF and BRINDA methods;
and (b) compare the performance of ICF and BRINDA methods when used to adjust the MNS SZC
values. A secondary objective was to assess the relationship between inflammation adjusted SZC
values and stunting. It was expected that the prevalence of zinc deficiency in the Malawi MNS sample
would decrease after adjusting for inflammation, using either method, and that ICF would decrease
the values more modestly compared to BRINDA. Furthermore, a positive association between the
adjusted values of SZC and stunting was expected, because stunting is also a recommended indicator
of zinc assessment.
2. Material and Methods
Cross-sectional survey data from the Malawi MNS were used in this study. The Malawi MNS
represents a sub-sample of the wider Malawi Demographic and Health Survey (MDHS), that ran in
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2015–2016. The sampling design is presented in detail elsewhere [8]. In brief, a two-stage cluster
design was used to sample participants from all 28 districts of the country. A cluster was a standard
enumeration area, as defined by the Malawi population and housing census conducted in 2008.
For each of the 105 selected clusters, 22 households in rural, and 20 households in urban areas, were
randomly selected for inclusion in the study. In each household, men (ages 20–55 years), WRA (ages
15–49 years), SAC (ages 5–14 years) and PSC (ages 6–59 months) were recruited. Their serum samples
were analysed at the Children’s Hospital Oakland Research Institute (CHORI) in Oakland, USA,
for zinc concentration, and the VitMin laboratory in Willstaet, Germany for CRP and AGP.
Datasets for the four age groups were accessed from the DHS program database. The calculated
sample size for the MNS was 3243, but with a 90% response rate, data were collected on 3099 participants.
An amended dataset was created to exclude participants that did not consent to venepuncture blood
collection or were missing SZC, CRP or AGP values. Pregnant women and participants with negative
values or values equal to 0 in the variables mentioned above were also removed. A SZC of 125 µg/dL
was considered as the threshold, above which contamination was suspected; values above this level
were also removed [26].
2.1. Adjustments of SZC
Normality of SZC data in the different age groups was assessed using measures of central tendency
and histograms. The SZC values were adjusted separately for the four age groups using ICF and
BRINDA methods. For ICF, a stepwise approach was used. Firstly, serum CRP and AGP concentrations
were split into four categories: normal (CRP ≤ 5 mg/L and AGP ≤ 1.0 g/L), incubation (CRP > 5 mg/L
and AGP ≤ 1.0 g/L), early convalescence (CRP > 5 mg/L and AGP > 1.0 g/L), and late convalescence
(CRP ≤ 5 mg/L and AGP > 1.0 g/L). Then, the geometric means of each category were calculated, and
geometric mean ratios were determined, using the formula presented below:
ICFi =
GMre f
GMi
(1)
where GMref is the reference/normal group of inflammation, and (i) denotes each of the three
inflammation stages. Finally, ICFs were multiplied by each SZC observation in the respective
category to calculate the adjusted SZC.
The BRINDA approach used multivariate regression models of loge-transformed SZC values
(response variable), and loge-transformed CRP and AGP values (explanatory variables). Both CRP
and AGP were included in each model. CRP and AGP internal reference (IR) values were calculated
instead of using external references recommended by BRINDA. This was done to achieve uniformity
since BRINDA only has IR values for WRA and PSC. The IR values are the loge-transformed maximum
values of the lowest deciles of each inflammatory marker. Only participants with both CRP and AGP
(loge-transformed) above the IR were adjusted using the equation presented below, whereas those
with inflammatory markers below the IR were considered normal and not adjusted:
Adjusted serum zinc = exp
{
ln
(
SZCunadj
)
− β1
[
ln(CRPobs) − ln
(
CRPre f
)]
− β2
[
ln(AGPobs) − ln
(
AGPre f
)]}
(2)
where β1 and β2 are the coefficients derived from the regression equation. CRPobs and AGPobs denote
the observed CRP and AGP values for the respective individual, and CRPref and AGPref denote the
reference values. Regression results were interpreted as a percentage change in the response variable,
after the percentage change in each explanatory variable. This followed the log-log interpretation of
linear regression presented below: (
1.01β − 1
)
∗ 100 (3)
where β is the coefficient of the explanatory variable. Zinc deficiency was determined using the
National Health and Nutrition Examination Survey (NHANES) SZC cut-offs, as shown in Table 1
below [27]. BRINDA values were back-transformed before applying these cut-offs.
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Table 1. Recommended lower cut-offs (2.5th percentile) for serum zinc status, adapted from the
National Health And Nutrition Examination Survey (NHANES) II data [27].
Serum Zinc Concentration Values µmol/L (µg/dL) a
Age Group < 10 years > 10 years
Children Females Males
Non-Pregnant Pregnant b
Morning Fasting N/A 10.7 (70)
8.6 (56) 1st trimester:7.6
(50) 2nd/3rd trimester:
11.3 (74)
Morning non-fasting 9.9 (65) 10.1 (66) 10.7 (70)
Afternoon/evening 8.7 (57) 9.0 (59) 9.3 (61)
a Conversion factor: µmol/L = µg/dL ÷ 6.54. b Lower cut-offs controlled for time of day and fasting status.
2.2. Statistical Analyses
Analyses were conducted on age-distributed data and pooled data. Measures of central tendency
and histograms were used to assess the normality of distribution. Point estimates were made using
household-level sampling weights derived by MDHS. The MNS sample size was calculated to produce
estimates on the national level, regional level (North, Central, and South) and type of domicile (Rural
or Urban).
The means of the ICF and BRINDA adjusted SZC values were compared with the unadjusted
values using ANOVA. The Bland–Altman method was used to compare performance of the two
adjustment methods [28]. The clinical criteria for defining lack of agreement (bias) between the methods
was a difference in SZC of 1 µg/dL. This value was derived from the maximum standard error of the
cut-off values, which are used to define zinc deficiency in this study [27].
A sensitivity analysis was done to estimate the effect of normality of differences, on the limits of
agreement. A robust regression approach designed to deal with non-uniform differences, suggested by
Bland and Altman, was used [29]. The approach combines two regression models, to generate upper
and lower limits of agreement (LOA). The first model plots the difference between methods (D) against
the means of the two methods (M), to give:
D = x0 + x1M (4)
where x0 is the intercept of the regression and x1 is the coefficient. The obtained residuals (R) from this
first model are then regressed against the means of the two methods (M) to produce the second linear
equation, which is:
R = b0 + b1M (5)
In this model, b0 and b1 also denote the intercept and coefficient. If there is no significant
relationship between the residuals and M, only the first model is used to calculate the limits of
agreement. The limits of agreement can be calculated as:
D ± 1.96 ∗ SD (6)
For model 1 only, where SD is the standard deviation of the residuals from the regression, and
D± 2.46R (7)
for both models [29].
Stunting was determined in children under the age of 5 and defined as the length or height
for age, which was less than −2.0 Z-score below the median value of the reference population [30].
Associations between stunting and adjusted SZC values were assessed using Pearson’s Chi-square test
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for independence, with Rao and Scott adjustments for complex survey design. A p-value of < 0.05 was
considered significant for all the analyses.
2.3. Ethical Approval
Ethical clearance for the MNS was obtained from the National Health Science Research Committee
in Malawi, reference number NHSRC 15/5/1436. For this secondary data analysis, ethical approval
was obtained from the College of Medicine Research Ethics Committee (COMREC), protocol number
P.01/20/2915.
3. Results
Of the 3099 participants surveyed in the MNS, 267 (8.7%) of participants did not consent to
venepuncture blood collection during the survey, or were missing SZC, CRP or AGP values. Others
were pregnant (n = 34; 1.1%), had negative SZC values (n = 2; < 1%), had SZC values equal to 0 (n = 1;
< 1%), or were above the threshold, suggesting contamination (n = 35; 1.1%). These were removed
and 2760 participants remained. Measures of central tendency indicated a normal distribution of SZC
values for all age groups. Furthermore, both adjustment methods normalize distribution of the data,
by working with loge-transformed variables.
Among the participants, PSC had the lowest SZC mean ± standard deviation (SD) of 58.4 ±
14.9 µg/dL before inflammation adjustments, as shown in Table 2. The highest mean concentration of
62.4 ± 15.8 µg/dL was recorded in SAC; however, it was not much higher than the mean concentration
of men. Means of inflammatory markers were greatest in PSC, and lowest in WRA. The mean
concentration of CRP in PSC was 6.3 ± 14.5 mg/L, and that of AGP was 1.4 ± 0.8 g/L. SAC also had a
higher average concentration of CRP (4.3 ± 11.6 mg/L), however, they were below the threshold of
inflammation. Similar results were observed in men and WRA, whose mean concentrations of CRP
and AGP were below the threshold of inflammation.
Table 2. Summary of concentrations of SZC, CRP and AGP of the participants in the Malawi MNS.
Group Mean SZC ± SD (µg/dL) Mean CRP ± SD (mg/L) Mean AGP ± SD (g/L)
Men 62.3 ± 14.1 2.7 ± 6.1 0.7 ± 0.4
WRA 60.1 ± 14.4 2.5 ± 8.5 0.7 ± 0.4
SAC 62.4 ± 15.8 4.3 ± 11.6 1.0 ± 0.6
PSC 58.4 ± 14.9 6.3 ± 14.5 1.4 ± 0.8
Total 58.8 ± 15.0 5.9 ± 13.9 1.3 ± 0.8
WRA: women of reproductive age, SAC: school-age children, PSC: pre-school children, CRP: C-reactive Protein,
AGP: α-1-acid glycoprotein, SZC: serum zinc concentration.
3.1. Adjustment of Serum Zinc Concentration (SZC)
Table 3 presents the correction factors generated by the ICF approach. The correction factors
increased SZC of all inflammation categories of men, SAC and PSC (correction factors were above 1,
indicating a positive adjustment). The correction factor for WRA in the incubation stage was below 1.
This resulted in a negative adjustment of the SZC in this stage. This category of WRA also had the
highest mean SZC value of 62.7 ± 15.9 µg/dL compared to the other inflammation categories of the
same age group. The overall mean SZC value for WRA was 60.1 ± 14.4 µg/dL, similar to the normal
category (60.6 ± 15.2 µg/dL), and greater than the late convalescence category (56.1 ± 11.8 µg/dL).
Back-transformed IR values used as cut-offs for BRINDA adjustment are also presented in Table 3. For
AGP, the threshold for BRINDA adjustment was higher for children than adults. Among the children,
the highest reference value for AGP (0.56) was obtained in PSC. The highest reference value for CRP
was also derived in PSC; WRA had the second-highest IR followed by men, then SAC. All the IR values
for AGP and CRP were below the cut-off of determining inflammation used by the ICF approach.
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Table 3. Internal correction values for ICF and BRINDA that were used to adjust SZC values
for inflammation.
Group InflammationCategory
Correction Factors
(ICF)
Internal Reference Values
(BRINDA)
CRP AGP
Men 0.13 0.37
Normal -
Incubation 1.060
Early 1.049
Late 1.058
WRA 0.15 0.39
Normal -
Incubation 0.966
Early 1.008
Late 1.076
SAC 0.12 0.46
Normal -
Incubation 1.070
Early 1.164
Late 1.037
PSC 0.19 0.56
Normal -
Incubation 1.069
Early 1.105
Late 1.004
Table 4 presents data from the loge-transformed models that were fit to adjust the SZC values
using the BRINDA method. Four regression models were fitted for men, WRA, SAC and PSC. All linear
models were plotted with SZC as the dependent factor and inflammatory markers as the predictor
variables, and they indicated significant relationships. Model outputs showed that CRP was negatively
associated with SZC in all age groups, whereas AGP was negatively associated with SZC in three age
groups only. The multivariate models for SAC and PSC were highly significant (p < 0.001) compared
to those of WRA and men (p = 0.04, p = 0.01). Only CRP was significantly associated with SZC when
both CRP and AGP were included in the models for men, SAC, and PSC (p < 0.001). For WRA, both
inflammatory markers were not significant in the multivariate model. For men, a 1% increase in AGP
was associated with a 2% increase in SZC, and a 1% increase in CRP concentration was associated with
a 3% decrease in SZC. Across demographic groups, CRP had the highest percentage association with
SZC in men and the lowest percentage was observed in WRA. For WRA, a 1% increase of CRP and
AGP were associated with an SZC decrease of 0.7% and 3%, respectively. However, the significance
of this association was not very strong (p = 0.040). A 1% increase in AGP concentration of SAC was
associated with a 4% decrease of their SZC. This was the highest percentage of change observed for
AGP, across the demographic groups. SZC values of PSC were least strongly associated with AGP,
as an increase of 1% of AGP was associated with a 1% decrease in SZC.
Table 4. Regression outputs of SZC versus inflammatory markers for different demographic groups.
Group Log β-Coefficient Intercept (95% CI) R2 p-Value
CRP (95% CI) AGP (95% CI)
Men −0.033 (−0.056, −0.010) 0.022 (−0.061, 0.105) 61.83 (58.79, 65.01) 0.03 0.013
WRA −0.007 (−0.020, 0.006) −0.030 (−0.076, 0.015) 57.70 (56.23, 59.21) 0.01 0.047
SAC −0.021 (−0.032, −0.009) −0.037 (−0.081, 0.006) 59.40 (58.29, 60.53) 0.05 <0.001
PSC −0.026 (−0.035, −0.015) −0.013 (−0.046, 0.020) 58.12 (57.21, 59.04) 0.04 <0.001
WRA: women of reproductive age, SAC: school-age children, PSC: pre-school children, CRP: C-reactive Protein,
AGP: α-1-acid glycoprotein.3.2. Description of Serum Zinc Concentration (SZC) Data.
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The distribution of SZC data values, before and after correcting for inflammation are shown
in Figure 1. The mean ± SD SZC was 58.8 ± 15.0 µg/dL before adjustment, and it increased to
60.2 ± 15.4 µg/dL after ICF adjustment, and 62.4 ± 15.8 µg/dL after BRINDA adjustment. The medians
of the distribution were also close to the means, at 56.3 µg/dL, 60.6 µg/dL, and 60.5 µg/dL for unadjusted,
ICF, and BRINDA adjusted, respectively. A greater magnitude of change was observed on the high
concentration end of SZC compared to the low concentration end. The maximum observed SZC value
(125.0 µg/dL), changed by approximately 15 µg/dL, whereas the lowest observed value (15 µg/dL)
changed by approximately 1 µg/dL after both adjustment methods.
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method, and (c) after adjusting with BRINDA method. Dashed lines correspond to mean values.
3.2. Prevalence Point Estimates
Prevalence estimates of SZC deficiency, before and after adjustment, are shown in Table 5.
The unadjusted estimates presented here may vary from the figures presented in the MNS report, due
to differences in sample size as a result of data cleaning. The national prevalence of zinc deficiency
was 62% before adjustments and it decreased to 59% after ICF correction, and 52% after BRINDA
correction. Before adjustment, men had the highest prevalence of zinc deficiency across all the age
groups, followed by WRA. This order did not change following ICF adjustment, but it was reversed
when the values were adjusted by BRINDA. SAC had the largest decrease in prevalence estimate
when both ICF (6%) and BRINDA (11%) adjustments were made. Men had a modest decrease of 2%
following ICF adjustment, but a larger decrease with BRINDA (10%). Decreases in the prevalence
estimates of PSC followed a similar pattern as that of men. Overall, there were limited decreases in
zinc deficiency estimates of WRA with both methods.
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Table 5. Prevalence estimates of serum zinc deficiency and inflammation in Malawi presented across
multiple age groups.
Inflammation a Serum Zinc b
Unadjusted ICF BRINDA
Prev. (95% CI) Prev. (95% CI) Prev. (95% CI) Prev. (95% CI)
Men 14 (9, 22) 71 (60, 79) 69 (60, 78) 61 (48, 72)
WRA 14 (10, 17) 66 (59, 72) 65 (58, 71) 63 (56, 70)
SAC 34 (29, 39) 56 (48, 63) 51 (44, 59) 45 (38, 52)
PSC 57 (51, 62) 61 (55, 67) 58 (52, 64) 52 (46, 58)
Total 52 (47, 57) 62 (56, 67) 59 (53, 64) 52 (46, 58)
a Inflammation cut-offs: CRP ≤ 5 mg/L and AGP ≤ 1 g/L [11], b zinc deficiency cut-offs presented in Table 1.
The prevalence of inflammation was determined based on the cut-offs suggested by
Thurnham et al. [11], which combined CRP and AGP measures. PSC had the highest prevalence of
inflammation (57%) among the demographic groups, followed by SAC (34%). However, the change
in zinc deficiency of PSC was not reflective of this high inflammation rate of that age group. Men
had a very low prevalence of inflammation (14%), but had the largest magnitude of change following
BRINDA adjustments, compared to the other demographic groups. Data on zinc deficiency prevalence,
stratified by region, type of domicile and gender, is presented in Table S1. These data show no statistical
differences in zinc prevalence between the different regions or rural and urban dwellers (p > 0.050).
3.3. Differences in SZC Across The Three Groups
There was a significant difference in mean SZC of the unadjusted, ICF and BRINDA adjusted
values (p < 0.001). Post-hoc results from the Tukey HSD test indicated that the mean SZC following ICF
adjustment was higher than the mean of the unadjusted values (p < 0.010), with a mean difference of
1.21 µg/dL (95% CI: 0.22, 2.19). BRINDA adjusted values were also significantly higher than unadjusted
values (p < 0.001), with a bigger difference of 3.24 µg/dL (95% CI: 2.25, 4.22) between the means of
those two groups.
3.4. Assessment of Agreement Methods
There was a strong correlation between values adjusted by ICF and BRINDA methods, as shown
in Figure 2, (R2 = 0.99). There was thus a strong positive linear relationship between the values
adjusted by ICF and those of BRINDA. The regression equation was ICF = 0.19 + 0.96× BRINDA,
indicating that for each 1 µg/dL increase in BRINDA values, there was a 0.96 µg/dL increase in ICF
values. Differences between the methods were plotted against the means of the paired values in the
Bland–Altman plot. The data points showed a scattered but downward pattern, which grew wider as
the SZC increased. The plot showed a bias of −2.07 µg/dL (95% CI: −2.15, −2.00), indicating a lack
of agreement between the methods. On average, BRINDA adjusted SZC values were greater than
ICF adjusted values by more than 2 µg/dL, which is more informative than the linear equation. This
value exceeds the limit of clinical significance of 1 µg/dL, defined a priori. Furthermore, the confidence
interval, as presented, did not include the line of equality (0), which confirmed the significance of
the systematic difference between ICF and BRINDA approaches. The upper LOA was 1.82 µg/dL
(95% CI: 1.69, 1.95), and the lower LOA was −5.96 µg/dL (95% CI: −6.09, −5.84), indicating that for
95% of the data points, ICF-adjusted SZC values were between 1.82 µg/dL greater or 5.96 µg/dL less
than BRINDA-adjusted SZC values. There was an overlap of the 95% confidence intervals of the
estimates from both methods, suggesting that the true SZC values may lie between the estimates from
the two methods.
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Figure 2. Method comparisons between ICF and BRINDA approaches, presented as a linear correlation
in the left panel and Bland–Altman plot in the right panel.
The sensitivity analysis derived an intercept of x0 = −0.26 and a coefficient of x1 = −0.03, which
were used to calculate the regression LOAs. At the highest point of the regression line, upper LOA
was 3.01 [2.89, 3.14] µg/dL and lower LOA was −4.57 [−4.67, −4.44] µg/dL. At the lowest point of
the regression line, upper LOA was −0.49 [−0.62, −0.37] µg/dL and the lower LOA was −8.07 [−8.20,
−7.95] µg/dL. This gave a difference of 7.58 µg/dL between the upper and lower LOAs, which was
similar to the difference between the original LOAs (7.78 µg/dL). The difference between the parametric
and non-parametric LOAs was 0.2 µg/dL, which is not clinically meaningful; the regression graph is
presented as a supplement in Figure S1.
3.5. Association Relationships between Serum Zinc Concentration (SZC) and Stunting
There was no significant association between SZC and stunting in PSC. This was true for both
ICF adjusted SZC (X2 = 0.09, p = 0.828) and BRINDA adjusted SZC (X2 = 0.05, p = 0.864). Stunting
was ssess in 1050 PSC, of whom 34% were stunted. When stratified by gender, the prevalence
35% an 33% in female and male children, respectively. PSC aged 6–23 months (n = 314) h d a lo er
stunting prevalence of 24%, compared to those aged 24–59 months (n = 736), who had a prevalence of
39%. Fifty-nine percent of all the PSCs were zinc deficient after adjusting for ICF, an 34% of them
were also stu ted. Furthermore, 35% PSC, with normal SZC in this adjustment method, were also
stunted. These results showed no difference in the prevalence of tunting between zinc d ficient
children, and those with n rmal SZC. Fo BRINDA, 52% of PSC were zi c deficient a d 34% of th se
were stunted, whereas 34% of PSC with normal SZC were also stunt d. There was also o difference in
th prevalence of stunting between PSC with normal zinc level , a d those who were deficient after
adjusting with BRINDA.
4. Discussion
The prevalence of zinc deficiency in Malawi was re-estimated by correcting SZCs for inflammation,
using existing m thods among a nationally representative sample of the Malawi population. Both
methods reduced the prevalence of zinc deficiency in the Malawi population from 62% to 59% with
the ICF method, and fr m 62% to 52% with the BRINDA m thod. These results are consis ent with
current understanding that SZCs re depressed during inflammation [31]. Despite th d ction,
zinc deficiency was still widespread. Siyame et al. previously reported a high zinc deficiency
prevalence (>90%), among women from two rural locations in Malawi [32]. Huddle et al. found a
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zinc deficiency prevalence of > 40% among pregnant women, also living in a rural Malawi setting [33].
The estimated prevalence of deficiency in this current study varied between demographic groups.
At 52%, the prevalence of zinc deficiency in PSC in Malawi was the second-highest across African
countries [3]. SAC had a lower prevalence estimate (45%) compared to other demographic groups,
across both methods of adjustment. This is still above the WHO threshold of 20%, above which
a public health intervention aimed to improve zinc status is recommended [34]. The reduction in
national level zinc deficiency prevalence after ICF was only 3%, but for BRINDA, it was much higher
(10%). A 10% decrease in prevalence of zinc deficiency is significant for public health stakeholders,
because it can affect resource allocation for intervention projects. Furthermore, if the prevalence of zinc
deficiency in this population were closer to the threshold of public health concern (20%), a 10% change
could influence the decision of whether a public health intervention is necessary or not. Inflammation
adjustment of SZC is thus necessary to avoid overestimation of the problem.
The 2015–2016 MNS was the first national-level assessment of zinc deficiency in Malawi using
biochemical indicators. Previous studies have used dietary zinc supply data to estimate the risk of
zinc deficiency. These risks were reported as 33% in 2009 [35], and 57% in 2010–2011 [36], based on
nationally representative data from other surveys. The latter estimate was similar to what is observed
in the present study. Inadequate dietary zinc supplies are likely to be widespread in Malawi, since
diets are primarily plant-based and with high phytate content, which reduces zinc bio-availability [37].
A phytate: zinc ratio of > 15 is associated with low absorption of zinc [2]. Individual studies have
shown that diets in Malawi have high phytate: zinc molar ratios, e.g., ranging from 17–24 [32] to
30.2 [36]. These findings are not surprising, given that the Malawian diet is monotonous, with most
of the calorie contributions coming from maize, which has a phytate: zinc molar ratio of 23 [37].
Soil type is also an important factor to consider, because it affects micronutrient concentrations in
the food and consequently the dietary intake levels [38]. For example, Joy et al. found that zinc
concentration of some food items sampled in Malawi were affected by the type of soil where it was
grown [39]. This highlights the necessity of further investigating the zinc deficiencies with respect to
spatial variation.
Non-dietary factors, such as environmental enteric dysfunction [40], acute and persistent
diarrhea [41,42], and intestinal helminthic infections [43], can affect the absorption of zinc, and
consequently SZC. These illnesses have been detected in some Malawian population groups [40]. Zinc
deficiency has further been linked to genetic disorders such as sickle cell disease and thalassemia [44],
but also other micronutrients such as iron and calcium, all of which are endemic in tropical countries,
and may have contributed to the high levels if zinc deficiency [1]. The prevalence of inflammation
was high, especially in PSC and SAC. Inflammation usually occurs in response to an infection, though
other cases may be subclinical. In this study sample, it may have been caused by malaria, which was
reported in 28% of PSC and 42% of SAC or urinary schistosomiasis, which was found in 30% of PSC and
22% of SAC. Furthermore, anemia and iron deficiency are also strongly associated with infection [45],
and both were prevalent in the study population. This is all consistent with the observation that zinc
deficiency and inflammation prevalence were high in the MNS sample population.
The SZC values increased more when adjusted by the BRINDA method compared to the ICF
method. Similar results have been reported elsewhere [12,13]. Different methodological approaches
may have contributed to this poor agreement. Firstly, ICF uses combined thresholds of CRP (≤ or
>5 mg/L) and AGP (≤ or >1 g/L), to identify inflamed individuals for adjustment [11]. On the other hand,
BRINDA uses IR values presented in Table 3 as the cut-off points for adjustment. These values created
a lower threshold than that used by ICF, resulting in more serum values (about 80%) being corrected for
inflammation. The BRINDA group highlights a linear relationship between the inflammatory markers
and APR nutrients [21–23], which presents altered APR nutrient concentrations at levels below the
internationally accepted inflammation cut-offs of CRP (≤5 mg/L) and AGP (≤1.0 g/L) [46]. This lack of
consensus for cut-off marks for inflammation, needs to be explored further, to improve agreement of
the adjustment methods.
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The second methodological difference is the categorical adjustment by ICF, as opposed to the
continuous adjustment by BRINDA. Reports in the literature suggest that the extent of SZC depression
during inflammation is based on stage of inflammation but also severity of infection, which is
characterized by concentration of the inflammatory markers [16,47–49]. Based on this, an individual
who is in incubation (i.e., CRP > 5 mg/L and AGP ≤ 1.0 g/L), with a CRP concentration of 6 mg/L,
would be expected to have a lower magnitude of zinc depression compared to one with a CRP of
12 mg/L. As such, adjusting them using the same correction factor may under-adjust the more severe
case. Similarly, if the adjustment approach does not take inflammatory stage into account, it may
result in other cases being over or under-adjusted. In the context of these two methods, neither is
likely to adjust SZCs properly, since the ICF method focuses on stages of inflammation and disregards
severity, whilst the BRINDA method, through the linear adjustment, focuses on severity and disregards
inflammation stage. Both approaches can thus be improved if they incorporate the severity of the
inflammatory response in the different inflammation stages. One way of approaching this would be
to adjust the values using linear regression, but separately for each inflammatory stage. This could
improve the accuracy of each method, and consequently their agreement. Furthermore, there is a need
to explore and incorporate other markers of inflammation that better determine the severity of the case.
This would simplify the integration of severity in the inflammation stages.
For ICF adjustments, the correction factors that were derived using ICF did not differ much from
those found in previous studies, which adjusted SZC. For instance, Karakochuk et al. [14], found
correction factors of 1.01, 1.15, and 1.07 in incubation, early, and late convalescence categories of PSC
respectively, which is similar to what was observed and reported in Table 3. Mburu et al. [16] also
applied the ICF method to adjust SZC values of adults, and their correction factors ranged between
1.08 and 1.27, which was slightly higher than what was observed in this current study, for both men
and WRA. Notably, their study only included participants who had tested positive for HIV, which
introduces some bias in terms of susceptibility to infections.
The incubation category for WRA had the highest mean of SZC values across this age group,
resulting in a correction factor of < 1. Similar results have been observed in other studies that adjusted
for inflammation in WRA and PSC. Macdonell et al., Grant et al. and Fiorentino et al. all found a
correction factor of > 1 for soluble transferrin receptor, which is a positive APR [12,20,25]. Furthermore,
a correction factor of < 1 was reported for retinol-binding protein, which is a negative APR [25].
The correction factor is based on the ratio of inflammation group against the normal group, and an
inverse ratio will have an opposite effect on the results. The aim of adjusting negative APRs is to
increase the concentration values that are reduced by inflammation. Therefore, the reduction of other
values in the same data negates the purpose of this exercise. This poses the question of whether
it is necessary to adjust categories that exhibit such inverse ratios, or if APR normalization by ICF
should focus only on the categories which need the adjustment. These inverse ratios were mostly
observed in the incubation category in all the studies referenced above, which shows a gap in the
general understanding of the inflammatory response and APR interactions during early stages of
inflammation. It may be possible that SZC does not drop as much during the first 48 h of inflammation,
however, this has not been clearly described in the literature, and further research is needed.
Zinc plays an important role in growth, and poor zinc status in children may affect bone growth,
leading to stunting. When the prevalence of stunting is > 20%, it is indicative of an elevated risk of zinc
deficiency in the population [34]. The results show a stunting prevalence above this threshold in PSC, but
no association between stunting (yes/no), and adjusted SZC values of both ICF (X2 = 0.09, p = 0.828) and
BRINDA (X2 = 0.05, p = 0.864) methods. This has also been reported in other studies, such as Hess et al.,
who reviewed stunting and SZC data from national surveys of 20 countries and found conflicting
results when comparing zinc deficiency with stunting prevalence estimates [3]. The comparison was
made in 19 of the 20 surveys and graphical results showed that stunting under-presented the severity
of zinc deficiency in some of the countries, despite blood analyses showing high deficiency rates.
For countries like Nigeria and Afghanistan, stunting levels indicated a low risk of zinc deficiency (i.e.,
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a stunting prevalence of < 20%), whereas SZC showed a zinc deficiency prevalence of > 40% in both
countries. The risk of zinc deficiency was thus poorly predicted by stunting in most of these surveys.
Individual studies have not been able to determine direct relationships between SZC and stunting
using different approaches [14,50–52].
Causative factors of stunting have been inadequately explored in the literature, which poses a
challenge for its use as a functional indicator of zinc deficiency [50,53]. Zinc, as a type II nutrient,
contributes to growth through cell differentiation, and its deficiency induces growth restriction, because
the body prioritizes homeostatic balances over growth [54]. There are about nine other nutrients of
this type II, e.g., phosphorus, magnesium and amino acids which also contribute to tissue generation
and growth. A balanced supply of all these nutrients is necessary to ensure growth as such. Although
zinc deficiency causes growth faltering, it is not always solely responsible for poor growth. If there
was an adequate supply of zinc, but low supply of the other type II nutrients in a population, stunting
would still be observed. Whilst stunting is a potentially useful indicator of zinc deficiency, it is less
sensitive in populations with multiple nutrient deficiencies. Furthermore, stunting is only useful
for predicting zinc deficiency in children under the age of 5, whereas this study showed that zinc
deficiency is common in all age groups.
The recommendation to combine SZC with dietary data cannot be easily achieved at a national
level, because of various challenges. Comprehensive individual-level dietary data is not available
at national level in Malawi. Food consumption data is collected in household surveys, but this is of
limited value, given the interest in defining zinc deficiency among specific age or demographic groups.
Furthermore, many studies have shown no correlation between dietary zinc intake and SZC [55], which
also limits the accuracy of estimating zinc deficiency even when both indicators are used. These factors
highlight the challenges of population zinc assessment and support the findings of Lowe et al. [5], that
more research is required to identify novel zinc biomarkers.
Reports in the literature suggest that prior zinc deficiency could be the cause of increased
inflammation as opposed to inflammation lowering SZC [47]. The present study uses data from a
cross-sectional study design, which builds on the association of SZC and inflammation, making it
impossible to determine causality between these two, and this is a limitation of the study. Nonetheless,
the causal relationship between SZC and inflammation is worth investigating, through a controlled
experiment in future research. It is proven that inflammation causes SZC to decrease, however, there
is a high possibility that inflammation adjustment is only necessary for a fraction of the inflamed
persons. Better understanding of the causal relationship would contribute greatly to improvement of
the adjustment methods. Data quality issues were also identified in the study, as initial data exploration
showed clumping of the SZC values across all age groups. This may have occurred due to various
reasons such as data transfer from assay instruments, or reagent correction adjustments in the lab. This
poses another limitation of this study and highlights some of the potential challenges that occur with
the use of SZC alone as a biomarker for zinc deficiency.
5. Conclusions
Overall, adjusting for inflammation increased the SZC of the study participants, and thereby
decreased the estimated prevalence of zinc deficiency in Malawi. The prevalence of zinc deficiency
in the country remained high across all age groups, highlighting the need for nutrition policies and
interventions to combat this problem. The biggest changes were observed after BRINDA adjustment,
whereas ICF gave more modest changes. There were important differences in the results, depending
on the adjustment method employed. Further research is needed to explore this difference, and to
understand the mechanisms behind inflammation and SZC, which will help improve the inflammation
adjustment methodologies. Stunting in PSC was not associated with SZC. While stunting prevalence
may be useful to predict the risk of zinc deficiency, it may underestimate the severity of the problem,
and there is a need to develop better indicators of zinc deficiency.
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